MIRM
Mirum Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$100.90
+0.27%Aug 25, 2026, 08:09 UTC
BlackRock Inc. disclosed a new stake of 4,390,063 shares in Mirum Pharmaceuticals, Inc., valued at approximately $513.95 million, representing about 7.20% ownership, in a recent SEC filing.
Source:Aug 5, 2026, 00:00 UTC
Mirum Pharmaceuticals reported Q2 2026 financial results with total revenue of $176.2 million, including Livmarli net product sales of $128.7 million and bile acid medicines net product sales of $47.5 million, and a net loss of $67.2 million.
Jun 14, 2026, 20:35 UTC
The U.S. FDA accepted the New Drug Application for zilurgisertib in fibrodysplasia ossificans progressiva under Priority Review.
Jun 14, 2026, 20:35 UTC
Mirum Pharmaceuticals and Incyte announced positive pivotal Phase 2 results from the PROGRESS study of zilurgisertib in fibrodysplasia ossificans progressiva.
Source: